title: New hope for therapy in neurodegenerative diseases.
abstract: The use of genetic screens to define cellular pathways that regulate neurodegenerative disease proteins has emerged as a powerful strategy to identify potential therapeutic targets for these disorders. Using cross-species genetic screens, Park et al. recently identified RAS-MAPK-MSK1 as a cellular pathway that modulates levels of the polyglutamine-containing protein ATXN1 and its subsequent toxicity in SCA1.
authors.affiliation: Department of Neurology, University of Michigan, A. Alfred Taubman Medical Research Institute, Ann Arbor, MI 48109-2200, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: do Carmo Costa
authors.forename: Henry L
authors.initials: HL
authors.lastname: Paulson
mesh_terms: D000818:Animals; D004331:Drosophila melanogaster / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000378:metabolism* / Q000633:toxicity*; D009687:Nuclear Proteins / Q000378:metabolism* / Q000633:toxicity*; D038744:Ribosomal Protein S6 Kinases, 90-kDa / Q000378:metabolism*; D020754:Spinocerebellar Ataxias / Q000378:metabolism* / Q000473:pathology*; D018631:ras Proteins / Q000378:metabolism*
chemical_list: D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D038744:Ribosomal Protein S6 Kinases, 90-kDa; D020928:Mitogen-Activated Protein Kinases; D018631:ras Proteins